| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Maureane Hoffman | Q42882680 |
| P2093 | author name string | Dougald M Monroe | |
| Harold R Roberts | |||
| P2860 | cites work | Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. | Q50335788 |
| Thrombin-mediated feedback activation of factor XI on the activated platelet surface is preferred over contact activation by factor XIIa or factor XIa. | Q50335789 | ||
| Prothrombin is a cofactor for the binding of factor XI to the platelet surface and for platelet-mediated factor XI activation by thrombin | Q56765883 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1381-1389 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Arteriosclerosis, Thrombosis, and Vascular Biology | Q4797542 |
| P1476 | title | Platelets and thrombin generation | |
| P478 | volume | 22 |
| Q55038787 | A Fibrin Cross-linking Polymer Enhances Clot Formation Similar to Factor Concentrates and Tranexamic Acid in an in vitro Model of Coagulopathy. |
| Q37550156 | A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes |
| Q34986144 | A comprehensive model for the humoral coagulation network in humans. |
| Q46320328 | A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation |
| Q48096062 | A microengineered vascularized bleeding model that integrates the principal components of hemostasis. |
| Q33405052 | A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia |
| Q38145567 | A platelet-inspired paradigm for nanomedicine targeted to multiple diseases |
| Q41850419 | A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery. |
| Q51769781 | A time course study on prothrombotic parameters and their modulation by anti-platelet drugs in hyperlipidemic hamsters. |
| Q34149960 | A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia |
| Q30443003 | ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia |
| Q42320997 | Activation of protease-activated receptors 3 and 4 accelerates tissue factor-induced thrombin generation on the surface of vascular smooth muscle cells |
| Q38235951 | Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes |
| Q36864696 | Ageing, oestrogen, platelets and thrombotic risk |
| Q35150059 | Alboserpin, a factor Xa inhibitor from the mosquito vector of yellow fever, binds heparin and membrane phospholipids and exhibits antithrombotic activity |
| Q53480847 | Altered Flow Changes Thrombin Generation Rate of Circulating Platelets. |
| Q91902907 | An αIIbβ3- and phosphatidylserine (PS)-binding recombinant fusion protein promotes PS-dependent anticoagulation and integrin-dependent antithrombosis |
| Q36940793 | Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention |
| Q37379382 | Anti-thrombogenic properties of a nitric oxide-releasing dextran derivative: evaluation of platelet activation and whole blood clotting kinetics |
| Q24310458 | Anticoagulant and antithrombotic properties of platelet protease nexin-1 |
| Q52718448 | Anticoagulant mechanism, pharmacological activity, and assessment of preclinical safety of a novel fibrin(ogen)olytic serine protease from leaves of Leucas indica. |
| Q40218722 | Anticoagulant therapy in acute coronary syndromes |
| Q44904202 | Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction. |
| Q36302146 | Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review |
| Q35208004 | Antiplatelet pretreatment does not increase hematoma volume in experimental intracerebral hemorrhage |
| Q28167737 | Antiplatelet therapy in cardiovascular disease |
| Q42217401 | Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin |
| Q39444308 | Antithrombotic activity of a newly synthesized coumarin derivative 3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-N-{2-[3-(5-hydroxy-2,2-dimethyl-chroman-6-yl)-propionylamino]-ethyl}-propionamide |
| Q34775088 | Antithrombotic and antiplatelet activities of Soshiho-tang extract |
| Q34268861 | Antithrombotic and profibrinolytic activities of eckol and dieckol |
| Q55098431 | Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade. |
| Q37897474 | Arterial thrombus formation in cardiovascular disease |
| Q41876554 | Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement |
| Q36661832 | Basic aspects of bypassing agents. |
| Q28168650 | Bivalirudin: an anticoagulant option for percutaneous coronary intervention |
| Q36044569 | Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases |
| Q37830708 | Blood coagulation factor Xa as an emerging drug target |
| Q33378580 | Blood coagulation, inflammation, and malaria |
| Q47096645 | Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? |
| Q36920715 | Causes and consequences of critical bleeding and mechanisms of blood coagulation |
| Q81142554 | Cell-based models of coagulation: a paradigm in evolution |
| Q38796239 | Characterization of IXINITY® (Trenonacog Alfa), a Recombinant Factor IX with Primary Sequence Corresponding to the Threonine-148 Polymorph. |
| Q41305826 | Characterization of coagulation factor synthesis in nine human primary cell types |
| Q45226003 | Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study |
| Q33403778 | Clinical characterization of canine platelet procoagulant deficiency (Scott syndrome). |
| Q35672990 | Clinical practice: the bleeding child. Part II: disorders of secondary hemostasis and fibrinolysis |
| Q40393685 | Clopidogrel: cardiologists' panacea or neurologists' headache? |
| Q36087858 | Clotting Mimicry from Robust Hemostatic Bandages Based on Self-Assembling Peptides |
| Q38059460 | Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis |
| Q36615273 | Coagulation cascade |
| Q35926044 | Comparative aspects of blood coagulation |
| Q48156313 | Curcumin, hemostasis, thrombosis, and coagulation |
| Q55260306 | De novo assembly and annotation of Hyalomma dromedarii tick (Acari: Ixodidae) sialotranscriptome with regard to gender differences in gene expression. |
| Q50991188 | Dehydration of blood platelets by zeodration: in vitro characterization and hemostatic properties in vivo. |
| Q36715734 | Diagnostic approach to inherited bleeding disorders |
| Q42516903 | Differential effects of dialysis and ultrafiltrate from individuals with CKD, with or without diabetes, on platelet phosphatidylserine externalization |
| Q33902224 | Does activation of the blood coagulation cascade have a role in malaria pathogenesis? |
| Q41845013 | Effect of Hemodilution In Vitro with Hydroxyethyl Starch on Hemostasis |
| Q43262216 | Effects of acute hypervolemic fluid infusion of hydroxyethyl starch and gelatin on hemostasis and possible mechanisms |
| Q37396783 | Effects of artificial colloids on haemostasis |
| Q37044188 | Effects of unidirectional flow shear stresses on the formation, fractal microstructure and rigidity of incipient whole blood clots and fibrin gels |
| Q34469949 | Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography |
| Q36592844 | Exogenous modification of platelet membranes with the omega-3 fatty acids EPA and DHA reduces platelet procoagulant activity and thrombus formation |
| Q28180138 | Exposure of platelet membrane phosphatidylserine regulates blood coagulation |
| Q45013463 | Factor VIIa-mediated tenase function on activated platelets under flow |
| Q79198290 | Factor Xa-A pleuripotential protease |
| Q24200171 | Fibrinogen concentrate in bleeding patients |
| Q24236341 | Fibrinogen concentrate in severely bleeding patients for acquired hypofibrinogenaemia |
| Q38064967 | Fructus Gardenia (Gardenia jasminoides J. Ellis) phytochemistry, pharmacology of cardiovascular, and safety with the perspective of new drugs development |
| Q40562735 | Functional characterization of tissue factor in von Willebrand factor-dependent thrombus formation under whole blood flow conditions. |
| Q37112667 | Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane |
| Q90134975 | Hemoperfusion leads to impairment in hemostasis and coagulation process in patients with acute pesticide intoxication |
| Q35820397 | Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity |
| Q50563846 | Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology. |
| Q45889198 | High dose factor VIIa improves clot structure and stability in a model of haemophilia B. |
| Q89943293 | Impaired platelet-dependent thrombin generation associated with thrombocytopenia is improved by prothrombin complex concentrates in vitro |
| Q50754008 | Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. |
| Q46892256 | Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery |
| Q46432730 | Inhibitory effects of P2Y12 receptor antagonists on TRAP-induced platelet aggregation, procoagulant activity, microparticle formation and intracellular calcium responses in patients with acute coronary syndromes |
| Q28167653 | Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics |
| Q45237824 | Initiation and propagation of coagulation from tissue factor-bearing cell monolayers to plasma: initiator cells do not regulate spatial growth rate |
| Q90480697 | Integrating platelet and coagulation activation in fibrin clot formation |
| Q41934357 | Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII. |
| Q36984232 | Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies |
| Q45316926 | Intrinsic Pathway of Fibrin Clot Formation |
| Q37113633 | Is aprotinin safe to use in a cohort at increased risk for thrombotic events: results from a randomized, prospective trial in off-pump coronary artery bypass. |
| Q36281976 | Ixolaris binding to factor X reveals a precursor state of factor Xa heparin-binding exosite |
| Q33959279 | Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. |
| Q42326086 | Key role of integrin α(IIb)β (3) signaling to Syk kinase in tissue factor-induced thrombin generation |
| Q37166399 | Kinetic regulation of the binding of prothrombin to phospholipid membranes |
| Q30409863 | Lessons Learned from Animal Models of Inherited Bleeding Disorders |
| Q54751872 | Localization of heparin cofactor II in injured human skin: a potential role in wound healing. |
| Q43284777 | Long-term follow-up of atrial fibrillation patients in the NASPEAF study. Prospective evaluation of different antiplatelet treatments. |
| Q43161130 | Lonomia obliqua venomous secretion induces human platelet adhesion and aggregation. |
| Q34205116 | Measurement of procoagulant platelet subpopulations in whole blood: development of an assay for population-based studies. |
| Q49360165 | Meta-Analysis of the Safety and Efficacy of the Oral Anticoagulant Agents (Apixaban, Rivaroxaban, Dabigatran) in Patients With Acute Coronary Syndrome. |
| Q39329081 | Modeling thrombus formation and growth |
| Q35858490 | Molecular targeting of angiogenesis for imaging and therapy |
| Q36285316 | Multi-Constituent Simulation of Thrombus Deposition |
| Q44276050 | Neutrophil cathepsin G promotes prothrombinase and fibrin formation under flow conditions by activating fibrinogen-adherent platelets |
| Q26765488 | New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor? |
| Q28217816 | New anticoagulant options for ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction |
| Q37184197 | New drugs for atrial fibrillation |
| Q38419319 | New horizons in platelet research: understanding and harnessing platelet functional diversity. |
| Q31161741 | New insights into the spatiotemporal localization of prothrombinase in vivo |
| Q52641024 | Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. |
| Q38012153 | Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban |
| Q40256123 | On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells |
| Q27023547 | On the origin of microparticles: From "platelet dust" to mediators of intercellular communication |
| Q37943829 | Optimal use of platelet glycoprotein IIb/IIIa receptor antagonists in patients undergoing percutaneous coronary interventions |
| Q58735789 | Optimizing transfusion strategies in damage control resuscitation: current insights |
| Q51418884 | Organ-on-Chip Recapitulates Thrombosis Induced by an anti-CD154 Monoclonal Antibody: Translational Potential of Advanced Microengineered Systems. |
| Q81011117 | Patient-specific antithrombotic strategies: lessons not yet learned from the renal insufficiency paradigm |
| Q37662158 | Phospholipids: key players in apoptosis and immune regulation. |
| Q47966579 | Plasma levels of haemostatic factors in patients with pulmonary embolism on admission and seven months later. |
| Q33941766 | Plasmodium falciparum-infected erythrocytes induce tissue factor expression in endothelial cells and support the assembly of multimolecular coagulation complexes |
| Q81028266 | Platelet biology for the clinician-scientist: an evolution of understanding |
| Q51892930 | Platelet deposition in non-parallel flow: influence of shear stress and changes in surface reactivity. |
| Q28546748 | Platelet mechanosensing of collagen matrices |
| Q37940636 | Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome |
| Q38786396 | Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties. |
| Q26820857 | Platelet-based coagulation: different populations, different functions |
| Q37996098 | Platelet-mediated vascular dysfunction during acute lung injury |
| Q39870321 | Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity |
| Q33432917 | Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond |
| Q92106724 | Platelets in Skin Autoimmune Diseases |
| Q36325536 | Platelets in hemostasis and thrombosis: Novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis. |
| Q35536246 | Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, thrombosis, and atherosclerosis studies |
| Q33373149 | Primary and secondary hemostatic functionalities of rehydrated, lyophilized platelets |
| Q34052471 | Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation |
| Q90484536 | Procoagulant Phosphatidylserine-Exposing Platelets in vitro and in vivo |
| Q40018577 | Procoagulant properties of human MV3 melanoma cells |
| Q36717080 | Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets |
| Q46230278 | Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study. |
| Q27022009 | Protein disulfide isomerase a multifunctional protein with multiple physiological roles |
| Q35006603 | Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency |
| Q33430766 | Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting |
| Q28196500 | Prothrombotic and antithrombotic pathways in acute coronary syndromes |
| Q80852609 | Pseudoaneurysm in children: diagnosis and interventional management |
| Q34290997 | Purinergic signaling in early inflammatory events of the foreign body response: modulating extracellular ATP as an enabling technology for engineered implants and tissues |
| Q57044283 | Quantifying Platelet Margination in Diabetic Blood Flow |
| Q48002845 | Rapid generation of thrombin by atheroma and platelets |
| Q35812919 | Recombinant FVIIa |
| Q38228494 | Recombinant activated factor VII in clinical practice: a 2014 update |
| Q33365354 | Recombinant activated factor VII in patients at high risk of bleeding |
| Q38527508 | Recombinant activated factor VII: 30 years of research and innovation |
| Q36892185 | Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent |
| Q45875415 | Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date. |
| Q39961992 | Redefining the systemic inflammatory response |
| Q36274222 | Redox-dependent impairment of vascular function in sickle cell disease |
| Q91857050 | Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids |
| Q38622747 | Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution |
| Q40311475 | Role of procurement-related injury in early saphenous vein graft failure after coronary artery bypass surgery |
| Q44952814 | Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin |
| Q30481898 | Segregation of platelet aggregatory and procoagulant microdomains in thrombus formation: regulation by transient integrin activation |
| Q58390475 | Silver nanoparticles enhance thrombus formation through increased platelet aggregation and procoagulant activity |
| Q38589520 | Spatiotemporal regulation of coagulation and platelet activation during the hemostatic response in vivo |
| Q36802971 | State of the art in platelet function testing |
| Q48273511 | Systems biology insights into the meaning of the platelet's dual-receptor thrombin signaling. |
| Q38781617 | Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges |
| Q45880844 | The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia |
| Q38069578 | The emerging role of neutrophils in thrombosis-the journey of TF through NETs |
| Q35206747 | The evolving role of platelets in inflammation. |
| Q38212058 | The functional role of platelets in the regulation of angiogenesis |
| Q33397768 | The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies |
| Q37808230 | The multivalent activity of the tissue factor-thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention |
| Q38182640 | The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism. |
| Q34481022 | The plasma hemostatic proteome: thrombin generation in healthy individuals |
| Q27490448 | The role of saliva in tick feeding |
| Q37379818 | Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. |
| Q90058249 | Thrombin generation and bleeding in cardiac surgery: a clinical narrative review |
| Q28196701 | Thrombin generation by activated factor VII on platelet activated by different agonists. Extending the cell-based model of hemostasis |
| Q53640998 | Thrombin generation in vascular tissue. |
| Q44916643 | Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. |
| Q97533720 | Thrombocytopenia: is it a prognostic factor for development of post-hemorrhagic hydrocephalus in neonates? |
| Q92152870 | Thrombolytic Potential of Novel Thiol-Dependent Fibrinolytic Protease from Bacillus cereus RSA1 |
| Q37240160 | Tissue factor storage, synthesis and function in normal and activated human platelets |
| Q54293957 | Two subpopulations of thrombin-activated platelets differ in their binding of the components of the intrinsic factor X-activating complex. |
| Q35613448 | Update on treatment regimens: prophylaxis versus on-demand therapy |
| Q52694337 | Use of microfluidics to assess the platelet-based control of coagulation. |
| Q54975780 | Why Do Patients Bleed? |
| Q34568888 | Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro |
| Q38182740 | n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights |
Search more.